In Vitro to In Vivo Animals to Man

  • P. H. Bach
  • E. A. Lock

Table of contents

  1. Front Matter
    Pages i-xx
  2. Key Note Lecture

  3. Heavy Metal Toxicity

    1. R. A. Goyer, C. R. Weinberg, W. M. Victery, C. R. Miller
      Pages 11-20
    2. Gary L. Diamond, Thomas W. Clarkson, John B. Hursh, M. George Cherian
      Pages 21-31
    3. Harry Roels, Robert Lauwerys, Jean-Pierre Buchet, Alfred Bernard, Alfons Vos, Maurice Oversteyns
      Pages 33-36
    4. Alfred Bernard, Ali Ouled Amor, Harry Roels, Robert Lauwerys
      Pages 37-41
    5. Chiharu Tohyama, Naoko Sugihira, Kazuo T. Suzuki, Masataka Murakami, Hiroshi Saito
      Pages 43-49
    6. Vera R. Porter, Dora B. Weiner
      Pages 51-57
    7. R. O. Blackburn, D. N. Prashad, C. Whitehead
      Pages 65-70
    8. E. Elger, R. Sievers, B. Elger, C. J. Olbricht, H. Stolte
      Pages 71-74
    9. Z. H. Endre, L. G. Nicholls, P. J. Ratcliffe, J. G. G. Ledingham
      Pages 103-106
    10. H. J. Mason, L. J. Somervaille, D. R. Tennant, D. R. Chettle, M. C. Scott
      Pages 113-118
    11. F. Khalil-Manesh, H. C. Gonick, E. Weiler, V. Rosen, L. Roche, A. Mutti et al.
      Pages 119-126
    12. G. L. Diamond, P. E. Morrow, B. J. Panner, R. M. Gelein, R. B. Baggs
      Pages 127-132
    13. Winston Evering, Susan Haywood, Jim Trafford
      Pages 133-137
    14. Shiro Ueda, Yoko Wakashin, Hiromichi Yoshida, Teruo Mori, Yoshio Mori, Ryosaku Azemoto et al.
      Pages 139-145
  4. Aminoglycosides and Lithium

    1. S. Ibrahim, Z. Kallay, F. Clerckx-Braun, J. Donnez, Ph. Jacqmin, P. M. Tulkens
      Pages 177-181
    2. M. B. Carlier, B. Rollmann, P. Maldague, P. M. Tulkens, Z. Kallay
      Pages 183-187
    3. M. K. Chan, W. L. Ng
      Pages 201-206
    4. J. P. Morin, N. Thomas, H. Toutain, H. Borghi, J. P. Fillastre
      Pages 207-216
    5. H. Nakahama, M. Horio, T. Moriyama, Y. Fukuhara, Y. Orita, T. Kamada
      Pages 217-220
    6. Thierri Gilbert, Martine Lelievre-Pegorier, Bernadette Nabarra, Claudie Merlet-Benichou
      Pages 225-231
    7. J. P. Mallie, H. Smaoui, Cl. Billerey, M. Cheignon, J. Schaeverbke
      Pages 233-239
    8. C. Dorian, Ph. Catroux, J. C. Cal, J. Cambar
      Pages 253-256
    9. H. Th. Heidemann, K.-H. Brune, L. Gjessing, E. E. Ohnhaus
      Pages 263-267
  5. Cyclosporin

    1. Hans Dieperink, Henrik Starklint, Ejvind Kemp, Paul Peter Leyssac
      Pages 277-283
    2. Anne Dawnay, Michael Lucey, Carolyn Thornley, Robert Beetham, Bill Cattell, Roger Williams
      Pages 285-290
    3. P. H. Whiting, D. J. Propper, J. G. Simpson, J. McKay, M. C. Jones, G. R. D. Catto
      Pages 291-296
    4. P. H. Whiting, N. J. Saunders, K. J. Thomson, J. G. Simpson
      Pages 309-314
    5. Elvino J. G. Barros, Mirian A. Boim, Luiz A. R. Moura, Oswaldo L. Ramos, Nestor Schor
      Pages 315-323
    6. Miloslav Dobrota, Julian R. Louis
      Pages 325-330
  6. Platinum Anticancer Drugs

About this book


There has been a growing awareness that nephrotoxicity represents a key factor in human nephropathies, where, irrespective of the causative agent, only a few clinical end-effects are diagnosed. Thus nephropathies are generally classified as acute or chronic renal failure, malignancies or immunological changes. The weaknesses in diagnosing nephropathies arises because of the effective role the kidney plays in maintaining homeostasis, despite the fact that it has been extensively damaged. The frequencies of some type of chemically-induced acute renal failure is well documented, but the causes of chronic renal failure, malignancy, and other nephropathies are far more difficult to associate with a chemical aetiology. Many of the new therapeutic agents have important beneficial effects, but they are found to have marked nephrotoxic effects. Thus there is a growing urgency to increase the stringency of chemical safety evaluation for their potential nephrotoxic effects. This is strongly countered by the increased financial pressure to identify potentially nephrotoxic chemicals earlier in their development and humanitarian considerations to more closely relate animal test to the clinical situation. Part of the challenge may be achieved by the increasing use of in vitro techniques.


development etiology evaluation homeostasis immunology kidney renal failure safety toxicity

Editors and affiliations

  • P. H. Bach
    • 1
  • E. A. Lock
    • 2
  1. 1.The Robens Institute of Industrial and Environmental Health and SafetyUniversity of SurreyGuildford, SurreyUK
  2. 2.ICI Central Toxicology LaboratoryMacclesfield, CheshireUK

Bibliographic information

Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology